Cargando…

Target‐Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy

Bispecific antibodies (BsAbs) bind to two different targets, and create two binary and one ternary complex (TC). These molecules have shown promise as immuno‐oncology drugs, and the TC is considered the pharmacologically active species that drives their pharmacodynamic effect. Here, we have presente...

Descripción completa

Detalles Bibliográficos
Autores principales: Schropp, Johannes, Khot, Antari, Shah, Dhaval K., Koch, Gilbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430159/
https://www.ncbi.nlm.nih.gov/pubmed/30480383
http://dx.doi.org/10.1002/psp4.12369
_version_ 1783405733472108544
author Schropp, Johannes
Khot, Antari
Shah, Dhaval K.
Koch, Gilbert
author_facet Schropp, Johannes
Khot, Antari
Shah, Dhaval K.
Koch, Gilbert
author_sort Schropp, Johannes
collection PubMed
description Bispecific antibodies (BsAbs) bind to two different targets, and create two binary and one ternary complex (TC). These molecules have shown promise as immuno‐oncology drugs, and the TC is considered the pharmacologically active species that drives their pharmacodynamic effect. Here, we have presented a general target‐mediated drug disposition (TMDD) model for these BsAbs, which bind to two different targets on different cell membranes. The model includes four different binding events for BsAbs, turnover of the targets, and internalization of the complexes. In addition, a quasi‐equilibrium (QE) approximation with decreased number of binding parameters and, if necessary, reduced internalization parameters is presented. The model is further used to investigate the kinetics of BsAb and TC concentrations. Our analysis shows that larger doses of BsAbs may delay the build‐up of the TC. Consequently, a method to compute the optimal dosing strategy of BsAbs, which will immediately create and maintain maximal possible TC concentration, is presented.
format Online
Article
Text
id pubmed-6430159
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-64301592019-04-01 Target‐Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy Schropp, Johannes Khot, Antari Shah, Dhaval K. Koch, Gilbert CPT Pharmacometrics Syst Pharmacol Research Bispecific antibodies (BsAbs) bind to two different targets, and create two binary and one ternary complex (TC). These molecules have shown promise as immuno‐oncology drugs, and the TC is considered the pharmacologically active species that drives their pharmacodynamic effect. Here, we have presented a general target‐mediated drug disposition (TMDD) model for these BsAbs, which bind to two different targets on different cell membranes. The model includes four different binding events for BsAbs, turnover of the targets, and internalization of the complexes. In addition, a quasi‐equilibrium (QE) approximation with decreased number of binding parameters and, if necessary, reduced internalization parameters is presented. The model is further used to investigate the kinetics of BsAb and TC concentrations. Our analysis shows that larger doses of BsAbs may delay the build‐up of the TC. Consequently, a method to compute the optimal dosing strategy of BsAbs, which will immediately create and maintain maximal possible TC concentration, is presented. John Wiley and Sons Inc. 2019-01-08 2019-03 /pmc/articles/PMC6430159/ /pubmed/30480383 http://dx.doi.org/10.1002/psp4.12369 Text en © 2019 The Authors CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research
Schropp, Johannes
Khot, Antari
Shah, Dhaval K.
Koch, Gilbert
Target‐Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy
title Target‐Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy
title_full Target‐Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy
title_fullStr Target‐Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy
title_full_unstemmed Target‐Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy
title_short Target‐Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy
title_sort target‐mediated drug disposition model for bispecific antibodies: properties, approximation, and optimal dosing strategy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430159/
https://www.ncbi.nlm.nih.gov/pubmed/30480383
http://dx.doi.org/10.1002/psp4.12369
work_keys_str_mv AT schroppjohannes targetmediateddrugdispositionmodelforbispecificantibodiespropertiesapproximationandoptimaldosingstrategy
AT khotantari targetmediateddrugdispositionmodelforbispecificantibodiespropertiesapproximationandoptimaldosingstrategy
AT shahdhavalk targetmediateddrugdispositionmodelforbispecificantibodiespropertiesapproximationandoptimaldosingstrategy
AT kochgilbert targetmediateddrugdispositionmodelforbispecificantibodiespropertiesapproximationandoptimaldosingstrategy